Effector CD4 T cells convert transient responses to KRAS targeted therapy into long-term durable remissions in pancreatic cancer (AACRPanCa 2026) - Oct 15, 2026 - Abstract #B110; "These durable remissions were observed across multiple mouse models , in combination with multiple KRAS inhibitors (MRTX1133, daraxonrasib, adagrasib), and in tumors with acquired resistance to KRAS inhibition via YAP amplification. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026; 86(18_Suppl_2):Abstract nr B110."
Clinical • IO biomarker • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CD4 • CD8 • CDK1 • IFNG • IL21 • KRAS • TBX21
|
|
Li Qiang; Megan Hoffman; Jung-Ho Chun; Brendan Parent; Felix Hambitzer; Frank Peprah; Courtney Kureshi; Birkley Lim; Eugena Chang; Michael Walsh; Julissa Tello; Tavus Atajanova; Hojeong Shin; Corey Perkins; Rakeeb Kureshi; Yaniris Molina-Aponte; James Dougan; Chong Zuo; Lauren Brais; Thomas Clancy; James Cleary; Jason Hornick; Brandon Huffman; Joseph Mancias; George Molina; Mark Fairweather; Jonathan Nowak; Kimberly Perez; Douglas Rubinson; Sarah Slater; Ritchell van Dams; Jiping Wang; Brian Wolpin; Kwok-kin Wong; Harshabad Singh; Andrew Aguirre; David Baker; Michael Dougan; Stephanie Dougan
|